Search

Search Results

• FROM LEGACY TO INNOVATION: PIDOTIMOD’S EXPANDING THERAPEUTIC HORIZON Pidotimod: Revisiting a Classic Immunomodulator

  Claudio Ucciferri, Francesca Chiappini, Jacopo Vecchiet, Katia Falasca

  e2025057

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.057

  3029

  PDF: 1058

  HTML: 1319

• USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS

  Paola Mancino, Katia Falasca, Claudio Ucciferri, Eligio Pizzigallo, Jacopo Vecchiet

  e2010003

  2010-03-26

  https://doi.org/10.4084/mjhid.2010.003

  1185

  PDF: 554

  HTML: 957

• Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation Pidotimod in SARS-CoV-2 vaccination

  Claudio Ucciferri, Antonio Auricchio, Jacopo Vecchiet, Katia Falasca

  e2022023

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.023

  2190

  PDF: 593

  HTML: 280

• Pidotimod in paucisymptomatic SARS-CoV2 infected patients Pidotimod in COVID-19

  Claudio Ucciferri, Barone Mirko, Jacopo Vecchiet, Katia Falasca

  e2020048

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.048

  3268

  PDF: 1912

  HTML: 990

• Cardiac toxicity associated with HCV direct antiviral agents Heart in HCV DAAs therapy

  Claudio Ucciferri, Alessandro Occhionero, Jacopo Vecchiet, Katia Falasca

  e2018069

  2018-10-29

  https://doi.org/10.4084/mjhid.2018.069

  1661

  PDF: 1015

  HTML: 224